Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Caribou Biosciences (CRBU) Consolidated Net Income: 2020-2025

Historic Consolidated Net Income for Caribou Biosciences (CRBU) over the last 6 years, with Sep 2025 value amounting to -$29.4 million.

  • Caribou Biosciences' Consolidated Net Income rose 23.11% to -$29.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$158.8 million, marking a year-over-year increase of 3.88%. This contributed to the annual value of -$149.1 million for FY2024, which is 46.08% down from last year.
  • Latest data reveals that Caribou Biosciences reported Consolidated Net Income of -$29.4 million as of Q3 2025, which was up 38.21% from -$47.6 million recorded in Q2 2025.
  • Caribou Biosciences' Consolidated Net Income's 5-year high stood at -$13.2 million during Q1 2021, with a 5-year trough of -$47.6 million in Q2 2025.
  • For the 3-year period, Caribou Biosciences' Consolidated Net Income averaged around -$36.6 million, with its median value being -$38.2 million (2024).
  • As far as peak fluctuations go, Caribou Biosciences' Consolidated Net Income tumbled by 664.48% in 2021, and later skyrocketed by 44.86% in 2023.
  • Over the past 5 years, Caribou Biosciences' Consolidated Net Income (Quarterly) stood at -$18.5 million in 2021, then plummeted by 65.47% to -$30.6 million in 2022, then fell by 22.45% to -$37.4 million in 2023, then fell by 3.83% to -$38.9 million in 2024, then increased by 23.11% to -$29.4 million in 2025.
  • Its Consolidated Net Income was -$29.4 million in Q3 2025, compared to -$47.6 million in Q2 2025 and -$42.9 million in Q1 2025.